Links among Paroxetine-Induced Sexual Dysfunctions, Gender, and CYP2D6 Activity

The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impres...

Full description

Saved in:
Bibliographic Details
Published in:Journal of sex & marital therapy 2007-07, Vol.33 (4), p.343-355
Main Authors: ZOURKOVA, Alexandra, CESKOVA, Eva, HADASOVA, Eva, RAVCUKOVA, Barbara
Format: Article
Language:English
Subjects:
Adult
Antidepressive Agents, Second-Generation - administration & dosage
Antidepressive Agents, Second-Generation - adverse effects
Biological and medical sciences
Cytochrome P-450 CYP2D6 - genetics
Cytochrome P-450 CYP2D6 - metabolism
Czech Republic
Depression - drug therapy
Depression - genetics
Depression - metabolism
Dose-Response Relationship, Drug
Female
Humans
Libido - drug effects
Male
Medical sciences
Middle Aged
Neuropharmacology
Paroxetine - administration & dosage
Paroxetine - adverse effects
Pharmacology. Drug treatments
Phenotype
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Sexual Dysfunctions, Psychological - chemically induced
Sexual Dysfunctions, Psychological - metabolism
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impression-Severity of Illness Scale (CGIS) and Arizona Sexual Experience Scale (ASEX). The phenotype procedure showed 7 males and 12 females with extensive metabolic status (EM) and 10 males and 26 females with poor metabolic status (PM). No variation in therapeutic efficacy between male and female subjects classified as PM and those marked as EM was found. A significantly higher rate of sexual dysfunction (p = 0.01) was recorded among females with a PM phenotype.
ISSN:0092-623X
1521-0715
DOI:10.1080/00926230701385589